Core Viewpoint - Laimei Pharmaceutical reported a revenue of 198 million yuan for Q1 2025, marking a year-on-year increase of 9.54%, but faced a net loss of 13.78 million yuan due to intensified market competition and rising R&D costs [2][3] Group 1: Financial Performance - The company achieved a revenue of 198 million yuan, reflecting a year-on-year growth of 9.54% [2] - The net profit attributable to shareholders was -13.78 million yuan, indicating an increase in losses compared to the previous year [2] Group 2: Strategic Focus - Laimei Pharmaceutical is focusing on its strengths in traditional therapeutic areas such as oncology, digestive system, and specialty drugs, while enhancing the marketing of its core product, Kanalin [2] - The company is actively expanding Kanalin's market beyond thyroid indications and is pursuing international sales to increase global market share [2] Group 3: R&D and Innovation - The company has maintained a path of independent innovation, with R&D investment reaching 13.77 million yuan, a year-on-year increase of 33.71% [3] - Several innovative projects, including a nano carbon iron injection and personalized tumor vaccines, are progressing smoothly, ensuring a robust pipeline for future growth [3] - The company has successfully registered new drugs, including Nicorandil and Clindamycin Phosphate Injection, contributing to a more diversified product structure [3]

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：300006 证券简称：莱美药业 公告编号：2025-025 重庆莱美药业股份有限公司 第五届监事会第三十八次会议决议公告 表决结果：3 票同意、0 票反对、0 票弃权。 二、备查文件 1、重庆莱美药业股份有限公司第五届监事会第三十八次会议决议。 特此公告。 重庆莱美药业股份有限公司 监事会 重庆莱美药业股份有限公司（以下简称"公司"）监事会于 2025 年 4 月 17 日以通讯方式向全体监事送达召开第五届监事会第三十八次会议的通知。 本次会议于 2025 年 4 月 22 日在重庆市渝北区黄山大道杨柳路 2 号重庆市科学 技术研究院 B 栋 13 楼会议室以现场会议与通讯表决相结合方式召开。本次会议 应出席会议监事 3 名，实际出席会议监事 3 名。本次会议的召集、召开符合 《中华人民共和国公司法》《公司章程》及有关法律法规的规定。本次会议由公 司监事会主席袁媛女士主持。经出席会议监事审议和书面表决，形成了以下 决议： 一、审议通过了《关于 2025 年第一季度报告的议案》 监事会认为：《2025 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-024 重庆莱美药业股份有限公司 第五届董事会第四十四次会议决议公告 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《2025 年第一季度报告》。 表决结果：9 票同意、0 票反对、0 票弃权。 二、审议通过了《关于向上海浦东发展银行股份有限公司重庆分行申请 融资授信的议案》 与会董事同意公司向上海浦东发展银行股份有限公司重庆分行申请综合 授信额度人民币 30,000 万元，其中敞口额度 10,000 万元。敞口额度由重庆莱美 隆宇药业有限公司提供连带责任保证担保，追加公司位于重庆市南岸区月季路 8 号的土地及房产提供抵押担保。具体内容以双方签订的有效担保及业务合同为准。 表决结果：9 票同意、0 票反对、0 票弃权。 三、备查文件 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"）董事会办公室于 2025 年 4 月 17 日以通讯方式向全体董事送达召开第五届董事会第四十四次会议的通 知。本次会议于 2025 ...

Group 1 - The core viewpoint of the articles indicates a significant decline in certain financial metrics for the year 2024 compared to 2023, with notable percentage changes in various categories [1][2] - The financial data shows a drastic decrease in the metric labeled as "■■■■■■■■■■" with a change of -202.33% from 2023 to 2024, indicating a negative trend [1] - Another metric, "■■■■■■■■■," experienced a decrease of -10.66% from 2023 to 2024, suggesting a downward trajectory in performance [1] Group 2 - The total financial figure reported is 43175.65 million, with a percentage of 40.88% noted, indicating a substantial portion of the overall financial landscape [2] - The metric "■■■■■■■■■■600252" shows a value of 24742.61 million with a percentage of 23.43%, highlighting its significance in the overall financial context [2] - A specific entry labeled "■■■■(■■)■■■■■■■■■■■■■■■■■■(2144.78 ■■■■)" has a percentage of 2.03, which may reflect a minor but relevant aspect of the financial data [2]

莱美药业（300006）公告，2025年第一季度营收为1.98亿元，同比增长9.54%；净亏损1377.53万元，去 年同期净亏损457.53万元。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥198,396,229.11, representing a 9.54% increase compared to ¥181,120,476.19 in the same period last year[3] - The net loss attributable to shareholders for Q1 2025 was ¥13,775,322.52, compared to a loss of ¥4,575,299.38 in Q1 2024[3] - Total operating revenue for the current period reached ¥198,396,229.11, an increase of 9.5% compared to ¥181,120,476.19 in the previous period[20] - Net loss for the current period was ¥13,959,616.84, compared to a profit of ¥31,378.00 in the previous period[21] - Basic and diluted earnings per share were both reported at -0.0130, compared to -0.0043 in the previous period, reflecting a decline in profitability[21] Cash Flow - The net cash flow from operating activities was -¥42,007,338.52, a decrease of 153.02% from ¥79,222,721.89 in the previous year[11] - The company's cash flow from operating activities showed a decline, indicating potential challenges in cash generation[23] - Cash received from operating activities totaled 298,863,067.81, while cash paid for operating activities was 340,870,406.33, leading to a negative cash flow[24] - Total cash inflow from financing activities was 52,509,161.10, while cash outflow was 188,813,252.93, resulting in a net cash flow of -136,304,091.83[25] - The net increase in cash and cash equivalents was -222,800,277.40, down from an increase of 118,514,005.21 in the previous period[25] Assets and Liabilities - Total assets decreased by 7.51% to ¥2,641,469,294.02 from ¥2,855,799,671.54 at the end of the previous year[3] - The total current assets decreased from 1,770,099,007.74 RMB to 1,532,370,297.08 RMB[17] - The total non-current assets increased from 220,174,591.57 RMB to 241,121,244.03 RMB in long-term equity investments[17] - Total liabilities decreased to ¥768,310,894.67 from ¥972,467,655.35 in the previous period, showing improved financial leverage[19] - The company’s total liabilities decreased by 43.31% in short-term borrowings, from ¥242,914,255.80 to ¥137,700,000.00[8] Research and Development - Research and development expenses increased by 33.71% to ¥13,768,411.89 from ¥10,297,554.56 in the same period last year[9] - Research and development expenses increased to ¥13,768,411.89, up from ¥10,297,554.56 in the previous period, reflecting a focus on innovation[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 304,323[13] - The largest shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., holds 23.43% of shares, totaling 247,426,064 shares[13] - Shareholder Qiu Yu holds 10.52% of shares, totaling 111,090,200 shares, which are currently frozen[13] Other Income and Expenses - The company reported a significant decrease in other income, down 77.81% to ¥4,408,944.53 from ¥19,870,791.47 in Q1 2024[9] - Total operating costs increased to ¥207,297,310.76, up 8.5% from ¥190,903,145.49 in the previous period[20] - The company paid 59,535,625.16 in cash to employees during the period[24] Investments - The company participated in an investment of 40 million RMB in Guangdong Dongna Collaborative Industry Investment Partnership[15] - The company has received drug registration certificates for two specifications of injectable Nicorandil, 2mg and 12mg[16] - The company plans to continue the disposal of 674,800 shares held by Qiu Yu through centralized bidding due to overdue debts[15] - The company has a total of 188,688,328.50 RMB in inventory at the end of the reporting period[17] Asset Disposal - The company experienced a 212.91% increase in asset disposal gains, rising to ¥25,052.59 from ¥8,006.35 in Q1 2024[9]

一、对外投资概述 证券代码：300006 证券简称：莱美药业 公告编号：2025-022 重庆莱美药业股份有限公司 关于参与投资广东东纳协同产业投资合伙企业（有限 合伙）的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 3 月 4 日，重庆莱美药业股份有限公司（以下简称"公司"）召开 第五届董事会第四十二次会议和第五届监事会第三十六次会议审议通过了《关于 参与投资广东东纳协同产业投资合伙企业（有限合伙）的议案》。公司与德摩咨 询（深圳）有限公司、广州迈普再生医学科技股份有限公司、广州康臣药业有限 公司、丁骏和张适安签署《合伙协议》，以自有资金参与投资广东东纳协同产业 投资合伙企业（有限合伙）（以下简称"合伙企业"、"东纳协同"）。投资完 成后合伙企业认缴出资总额为人民币 9,100 万元，其中公司将作为该合伙企业的 有限合伙人认缴出资 4,000 万元，认缴完成后公司持有东纳协同 43.9560%的合伙 份额。具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn）上披露的《关 于参与投资广东东纳协同产业投资合伙 ...

关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 近日，重庆莱美药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的克林霉素磷酸酯注射液 2ml：0.3g 和 4ml：0.6g 两种规格《药 品补充申请批准通知书》，现将有关事宜公告如下： 药品名称 通用名称：克林霉素磷酸酯注射液 英文名/拉丁名：Clindamycin Phosphate Injection 剂型 注射剂 注册分类 化学药品 规格 2ml：0.3g（按 C₁ ₈ H₃ ₃ ClN₂ O₅ S 计） 4ml：0.6g（按 C₁₁H₁₁ClN₁O₁S 计） 包装规格 10 支/盒 4 支/盒 通知书编号 2025B01519 2025B01512 原药品批准文号 国药准字 H20043358 国药准字 H20043359 申请内容 注射剂仿制药质量与疗效一致性 评价，其他变更事项包括：1. 变更 药品的处方及其生产工艺（包括原 料药供应商）；2. 变更药品质量标 准。 注射剂仿制药质量与疗效一致性评 价，其他变更事项包括：1. 变更药品 的处方及其生 ...

北京市中伦律师事务所 关于重庆莱美药业股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年四月 本所及经办律师依据《中华人民共和国证券法》（以下简称"《证券法》"） 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法 定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律 意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在 虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本所律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、《证 券法》、《上市公司股东会规则》（以下简称"《股东会规则》"）及《深圳证 券交易所上市公司股东会网络投票实施细则》等法律、行政法规、规范性文件以 及《重庆莱美药业股份有限公司章程》（以下简称"《公司章程》"）的有关规 定出具本法律意见。 北京市中伦律师事务所 关于重庆莱美药业股份有限公司 2024 年年度股东大会的 法律意见书 致：重庆莱美药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受重庆莱美药业股份有限公 司（以 ...

特别提示： 重庆莱美药业股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300006 证券简称：莱美药业 公告编号：2025-020 1、本次股东大会无增加、变更、否决议案的情形； 一、会议召开和出席情况 重庆莱美药业股份有限公司（以下简称"公司"）2024年年度股东大会于2025 年3月22日以公告形式发出会议通知，现场会议于2025年4月11日（星期五）15:30 在重庆市渝北区黄山大道杨柳路2号重庆市科学技术研究院1期B栋13楼会议室 以现场表决与网络投票相结合的方式召开。本次股东大会由公司董事长梁建生先 生主持。公司董事、监事、高级管理人员和北京市中伦律师事务所见证律师出席 了本次会议。本次会议的召集、召开与表决程序符合法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。参加本次会议的股东及股东授权代表共计195 人，代表股份363,645,827股，占公司总股本的34.4391％。其中除公司董事、监 事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他股 东（以下简称"中 ...